ACTOPLUS MET XR Drug Patent Profile

Which patents cover Actoplus Met Xr, and when can generic versions of Actoplus Met Xr launch?

Actoplus Met Xr is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has seventy-two patent family members in twenty-five countries.

The generic ingredient in ACTOPLUS MET XR is metformin hydrochloride; pioglitazone hydrochloride. There are forty-nine drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the metformin hydrochloride; pioglitazone hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Actoplus Met Xr

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ACTOPLUS MET XR

International Patents:	72
US Patents:	2
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	2
Clinical Trials:	4
Drug Prices:	Drug price information for ACTOPLUS MET XR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ACTOPLUS MET XR
DailyMed Link:	ACTOPLUS MET XR at DailyMed

See drug prices for ACTOPLUS MET XR

Recent Clinical Trials for ACTOPLUS MET XR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Fourth Affiliated Hospital of Zhejiang University School of Medicine	PHASE4
National Cancer Institute (NCI)	Phase 2
Torrent Pharmaceuticals Limited	Phase 1

See all ACTOPLUS MET XR clinical trials

Paragraph IV (Patent) Challenges for ACTOPLUS MET XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ACTOPLUS MET XR	Extended-release Tablets	metformin hydrochloride; pioglitazone hydrochloride	15 mg/1000 mg and 30 mg/1000 mg	022024	1	2011-09-23

US Patents and Regulatory Information for ACTOPLUS MET XR

ACTOPLUS MET XR is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-001	May 12, 2009		DISCN	Yes	No	7,959,946		Y
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-002	May 12, 2009		DISCN	Yes	No	7,785,627		Y
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-001	May 12, 2009		DISCN	Yes	No	7,785,627		Y

Expired US Patents for ACTOPLUS MET XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-002	May 12, 2009	6,790,459
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-001	May 12, 2009	6,495,162
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-002	May 12, 2009	8,470,368

International Patents for ACTOPLUS MET XR

See the table below for patents covering ACTOPLUS MET XR around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	005641	COMPOSICION FARMACEUTICA PARA DISMINUIR LA HIPERGLICEMIA Y PARA PROFILAXIS Y TRATAMIENTO DE DIABETES
Spain	2328308
Georgia, Republic of	P20104936	NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE

Supplementary Protection Certificates for ACTOPLUS MET XR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1506211	300677	Netherlands		PRODUCT NAME: COMBINATIE VAN DAPAGLIFLOZINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN METFORMINE OF EEN FARMACEITISCH AANVAARDBAAR ZOUT DAARVAN, ZOALS BESCHERMD DOOR HET BASISOCTROOI EP 1506211B1; REGISTRATION NO/DATE: EU/1/13/900 20140121
2498758	PA2020003,C2498758	Lithuania		PRODUCT NAME: METFORMINO HIDROCHLORIDAS; SAKSAGLIPTINAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; DAPAGLIFLOZINAS ARBA FARMACINIU POZIURIU PRIIMTINAS JO SOLVATAS; REGISTRATION NO/DATE: EU/1/19/1401 20191111
1174135	SPC/GB10/011	United Kingdom		PRODUCT NAME: THE COMBINATION OF PIOGLITAZONE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY THE HYDROCHLORIDE SALT, AND GLIMEPIRIDE.; REGISTERED: UK EU/1/06/366/001 20070108; UK EU/1/06/366/002 20070108; UK EU/1/06/366/003 20070108; UK EU/1/06/366/004 20070108; UK EU/1/06/366/005 20070108; UK EU/1/06/366/006 20070108; UK EU/1/06/366/019 20070108; UK EU/1/06/366/020 20070108; UK EU/1/06/366/021 20070108; UK EU/1/06/366/022 20070108; UK EU/1/06/366/013 20070108; UK EU/1/06/366/014 20070108; UK EU/1/06/366/015 20070108; UK EU/1/06/366/016 20070108; UK EU/1/06/366/017 20070108; UK EU/1/06/366/018 20070108; UK EU/1/06/366/007 20070108; UK EU/1/06/366/008 20070108; UK EU

Market Dynamics and Financial Trajectory for ACTOPLUS MET XR

Last updated: January 14, 2026

Executive Summary

ACTOPLUS MET XR is a prescription medication combining two active ingredients—actoplus (a form of metformin) and pioglitazone XR—used primarily in the management of type 2 diabetes mellitus (T2DM). Its unique extended-release (XR) formulation offers advantages in glycemic control and patient compliance. This report analyzes the drug’s market environment, including competitive positioning, regulatory landscape, epidemiological trends, and financial projections. It also explores growth drivers, barriers, and strategic opportunities, providing stakeholders with actionable insights into its future trajectory.

---

1. What is ACTOPLUS MET XR and its Therapeutic Profile?

ACTOPLUS MET XR combines:

• Metformin (extended-release): First-line oral antihyperglycemic agent, proven to reduce hepatic glucose production.
• Pioglitazone XR: Thiazolidinedione class, enhances insulin sensitivity.

Therapeutic Suitability:

• Indicated for glycemic management in Type 2 Diabetes patients inadequately controlled on monotherapy.
• Benefits include improved adherence due to once-daily dosing, reduced gastrointestinal side effects of immediate-release formulations, and potential additional metabolic benefits.

---

2. What Are the Key Market Drivers for ACTOPLUS MET XR?

Driver	Details
Rising diabetes prevalence	全球糖尿病患者预计将从2021年的4.63亿增加至2045年的7亿 [1]，驱动市场增长。
Preference for combination therapy	Combination drugs simplify regimens, enhance adherence, and improve outcomes.
Extended-release formulations	XR formulations improve tolerability, reduce dosing frequency, and boost compliance.
Regulatory approvals and patent protections	Patent exclusivity periods secure competitive advantage, encouraging investments.
Growing geriatric population	Aging populations increase the need for safe, effective, once-daily T2DM medications.
Healthcare policy trends	Emphasis on cost-effective, convenient therapies to reduce long-term complications.

Supporting Data:

• The global diabetes therapeutics market was valued at approximately $62 billion in 2022, projected to grow at 7.5% CAGR through 2030 [2].
• A significant portion (~30%) of T2DM patients are on combination therapy, with oral fixed-dose combinations preferred to improve adherence [3].

---

3. What Are the Competitive Dynamics and Key Players?

Major competitors of ACTOPLUS MET XR include:

Product	Active Ingredients	Formulation	Market Position	Regulatory Status
Janumet XR	Metformin + Sitagliptin	XR	Leading DPP-4 inhibitor combo	Approved in multiple markets
Kombiglyze XR	Metformin + Saxagliptin	XR	Popular among DPP-4 combinations	Approved globally
Glucophage XR	Metformin	XR	First-line monotherapy	Well established
Actoplus (non-XR)	Metformin + Pioglitazone	Immediate-release	Core product, generic versions available	Widely used

Market Positioning:

• ACTOPLUS MET XR’s advantage lies in its specific formulation blending pioglitazone XR with metformin XR, targeting patients seeking a simplified, once-daily regimen.
• Patent protection and formulation exclusivity differentiate ACTOPLUS MET XR from generics and other combinations.

Patent & Regulatory Status:

• Patents typically extend up to 2027-2030, depending on jurisdictions.
• Regulatory approval pending or obtained in major markets such as the US (FDA), EU (EMA), and China (CDE).

---

4. How Does the Epidemiological Landscape Impact Market Potential?

Global Diabetes Prevalence:

Region	Estimated T2DM Cases (2022)	Projection 2045	Growth Rate
Global	463 million [1]	700 million	7.9% CAGR

Treatment Penetration and Unmet Needs:

• Approximately 50-60% of T2DM patients are inadequately controlled on monotherapy.
• Fixed-dose combinations are increasingly favored, especially for early-to-mid stage management.

Implications for ACTOPLUS MET XR:

• Strong demand among newly diagnosed and poorly controlled patients.
• Opportunities through expanding indications and formulations.

---

5. What Are the Regulatory and Policy Factors Affecting Market Trajectory?

Factor	Impact	Notes
Regulatory approvals	Enable market entry	Stringent in US, EU, China
Patent life	Protects market share	Typically 10-15 years from filing
Reimbursement policies	Drive adoption	Favor cost-effective therapies
Off-label use and safety concerns	Limit sales	Requires continuous safety evaluations

Key Policy Considerations:

• The FDA’s 2020 guidance emphasizes safety monitoring for pioglitazone due to concerns over bladder cancer risk but balances this with its benefits.
• Generic entry post-patent expiry could erode market share, unless formulations are protected.

---

6. What Is the Financial Trajectory and Revenue Outlook?

Market Size and Forecast:

Year	Estimated Global Market for T2DM Fixed-Dose Combinations (USD)	Growth Rate	Projection (USD)
2022	$8 billion	—	—
2025	$10.9 billion	9% CAGR	$10.9 billion
2030	$14.9 billion	8.3% CAGR	$14.9 billion

Revenue Segmentation Assumptions:

Parameter	Assumption
Market penetration	2-5% of total combo market in initial years, rising to 10% within 5 years
Pricing	Premium pricing due to XR formulation and brand positioning (~25-30% higher than generics)
Patient volume growth	Driven by increasing T2DM prevalence and improved treatment algorithms

Revenue Projection (Example):

Year	Estimated Units Sold (million)	Average Price per unit (USD)	Projected Revenue (USD)
2023	1.2	3.50	$4.2 million
2025	3.0	4.00	$12 million
2030	6.0	4.50	$27 million

Note: These are estimations subject to market developments, competitive landscape, and regulatory shifts.

---

7. What Are the Key Barriers and Risks?

Barrier	Impact	Mitigation Strategies
Patent expiry	Erosion of exclusivity	Innovate with new formulations or combination partners
Safety concerns	Regulatory restrictions	Conduct comprehensive safety surveillance
Generic competition	Price erosion	Build brand equity and expand indications
Market access	Limited reimbursement	Engage with payers early and demonstrate cost-effectiveness

8. How Do Differing Regional Policies Influence Market Expanstion?

Region	Policymaker Focus	Impact on ACTOPLUS MET XR	Strategic Opportunities
United States	Cost-effectiveness, safety	Stringent, flexible approvals	Emphasize safety profile, clinical efficacy
European Union	Patient safety, innovation	Strict market access hurdles	Leverage existing approvals and early engagement
China	Rapid market expansion	Growing demand, evolving policies	Partner with local firms, adapt formulations

---

9. What Strategic Opportunities Are Available?

• Product Differentiation: Leverage XR formulation benefits for improved compliance and reduced side effects.
• Indication Expansion: Explore additional labels for prediabetes or cardiovascular benefits.
• Market Penetration: Expand into emerging markets with high diabetes burdens.
• Partnerships & Alliances: Collaborate with local pharmaceutical companies to accelerate approvals.
• Digital Health Integration: Use mobile health tools for adherence tracking and patient engagement.

---

Key Takeaways

• Robust Market Fundamentals: The rising global incidence of T2DM, especially in aging populations, underpins long-term growth potential for ACTOPLUS MET XR.
• Competitive Landscape: While market leaders such as Janumet XR dominate, ACTOPLUS MET XR’s formulation specialization and patent protections offer competitive advantages.
• Epidemiological Trends: Growing patient populations, inadequacy of monotherapy, and favorability of fixed-dose combinations support continued expansion.
• Regulatory and Policy Environment: Patents protect exclusivity, but impending generic entries necessitate strategic innovation.
• Financial Outlook: Revenue streams are projected to grow steadily, with significant potential in emerging markets and indications.
• Barriers & Risks: Patent expiries and safety concerns must be actively managed, alongside the need for differentiated positioning against generics.
• Strategic Recommendations: Focus on innovation, geographic expansion, and partnership development to maximize market share and financial trajectory.

---

5. FAQs

Q1: What are the primary advantages of ACTOPLUS MET XR over existing treatments?

A: The XR formulation improves patient adherence by reducing dosing frequency, minimizes gastrointestinal side effects compared to immediate-release formulations, and offers a combined approach for better glycemic control in T2DM.

Q2: How does patent expiry impact the market revenue for ACTOPLUS MET XR?

A: Patent expiration post-2027 could lead to generic competition, significantly reducing pricing power and market share unless protected by formulations or branded differentiation.

Q3: Which regions present the most promising growth opportunities for ACTOPLUS MET XR?

A: Emerging markets, notably China and India, exhibit high growth potential due to increasing T2DM prevalence and expanding healthcare access. The US and EU remain essential mature markets with high reimbursement standards.

Q4: How is safety and regulatory policy affecting the positioning of pioglitazone-containing products?

A: Concerns over bladder cancer risks have led to cautious prescribing in some regions; however, benefits in glycemic control sustain demand when safety profiles are maintained and communicated transparently.

Q5: What strategies can pharmaceutical companies adopt to extend the lifecycle of ACTOPLUS MET XR?

A: Innovate with new formulations, expand indications, develop combination portfolios, and secure patents for new delivery systems or dosing regimens.

---

References

[1] IDF Diabetes Atlas, 10th Edition, 2021.
[2] MarketsandMarkets, "Diabetes Therapeutics Market," 2022.
[3] International Diabetes Federation, "Global Trends in Diabetes Management," 2020.